As retrospective data collection is unsatisfactory, there is a need for childhood vaccination with hepatitis B to be registered on databases to generate appointments and audit uptake. This should be in place now that universal antenatal screening for hepatitis B surface antigen has been recommended.³

Contributors: DEW designed the audit, collected and analysed the data, and participated in writing the paper with EHB. EHB provided DEW with the list of subjects to be investigated, discussed core ideas, and participated in writing the paper; she

maintains the database of mothers who are hepatitis B positive and advises on appropriate immunisations. EHB will act as guarantor for the paper.

Competing interests: None declared.

- 1 Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. *N Engl J Med* 1975;292:771-4.
- 2 Boxall EH. In: A Zuckerman, ed. *Prevention of hepatitis B in the newborn, children and adolescent*. London: Royal College of Physicians, 1996.
- 3 Department of Health. Screening of pregnant women for hepatitis B and immunisation of babies at risk, 1998. (HSC 1998/127.)

(Accepted 10 December 1998)

Drug points

Cyclosporin neurotoxicity after chemotherapy

Deborah A Tweddle, Kevin P Windebank, Quentin Campbell Hewson, S Murray Yule, Department of Paediatric Oncology, Institute of Child Health, Royal Victoria Infirmary NHS Trust and University of Newcastle, Newcastle upon Tyne NE1 4LP

Cyclosporin neurotoxicity may result from interaction with chemotherapy used for transplant conditioning^{1,2} and to reverse multidrug resistance.³ We describe a case of neurotoxicity after chemotherapy for post-transplantation lymphoproliferative disease.

A 9 year old boy presented with monoclonal post-transplantation lymphoproliferative disease six years after cardiac transplantation for congenital heart disease. He was taking azathioprine and cyclosporin (Neoral) 90 mg twice daily (6 mg/kg/day) with whole blood trough concentrations between 29 µg/l and 288 µg/l (Behring enzymatic assay) in the six months before diagnosis. Azathioprine treatment was discontinued, cyclosporin was reduced to 70 mg twice daily, and three courses of low dose chemotherapy were given: vincristine 1.5 mg/m², cyclophosphamide 300 mg/m², and 7 days of prednisolone 60 mg/m². Five triple intrathecal injections of methotrexate and hydrocortisone 15 mg and cytarabine 30 mg were also given. This was followed by high dose treatment: methotrexate 1 g/m², cyclophosphamide 2 g/m², vincristine, prednisolone, and one triple intrathecal injection as before.

Six days after starting high dose chemotherapy he presented with headache, fever (38°C), seizures, and visual agnosia. Abnormal serum concentrations included urea 11.9 mmol/l (2.5-6.4 mmol/l), magnesium 0.56 mmol/l (0.6-1.0 mmol/l), alanine aminotransferase 156 IU/l (<31 IU/l), and bilirubin 23 µmol/l (3-19 µmol/l). His cyclosporin concentration was 250 µg/l and his methotrexate concentration was 0.1 µmol/l (<0.1 µmol/l). An electroencephalogram showed diffuse slow wave activity, but a cranial contrast enhanced computed tomogram and results of lumbar puncture were both normal. Cyclosporin was discontinued and intravenous magnesium, broad spectrum antibiotics, aciclovir, phenobarbital, and diazepam were given. His condition improved, but concern over the possibility of rejection led to reintroduction of cyclosporin at the previous dose. Three days later he became confused, with auditory and visual hallucinations, hypertension, a parkinsonian-type tremor, and rigidity. His cyclosporin concentration was 219 µg/l and serum magnesium was 0.7 mmol/l. Magnetic resonance imaging of his brain showed abnormal, symmetrical non-enhancing signals throughout the parietal and occipital lobes (figure). Cyclosporin neurotoxicity was diagnosed.¹⁻³ The drug was withdrawn and his neurological abnormalities resolved. Three further courses of chemotherapy were given with no clinical evidence of rejection.

Magnetic resonance scan of head showing abnormal signal throughout cortex and white matter of the parietal and occipital lobes

To our knowledge, neurotoxicity has not been reported for cyclosporin when given with chemotherapy for post-transplantation lymphoproliferative disease. The temporal association between chemotherapy and the onset of symptoms implies that neurotoxicity was related to an interaction between cyclosporin and high doses of cyclophosphamide,¹ perhaps through inhibition of cytochrome P-450 enzymes⁴, and possibly to prednisolone,² vincristine,³ and methotrexate.³ We advise clinicians to be cautious if continuing cyclosporin during chemotherapy as normal concentrations do not preclude toxicity.

- 1 Ghany AM, Tutschka PJ, McGhee RB, Avalos BR, Cunningham I, Kapoor N, et al. Cyclosporine-associated seizures in bone marrow transplant recipients given busulphan and cyclophosphamide preparative therapy. *Transplantation* 1991;52:310-5.
- 2 Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne RD, Graeb DA, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. *Bone Marrow Transplant* 1991;8:393-401.
- 3 Bertrano Y, Capdeville R, Balduck N, Phillippe N. Cyclosporin A used to reverse drug resistance increases vincristine neurotoxicity. *Am J Hematol* 1992;40:158-9.
- 4 Leblanc GA, Waxman DJ. Mechanisms of cyclophosphamide action on hepatic P-450 expression. *Cancer Res* 1990;50:5720-6.
- 5 O'Sullivan DP. Convulsions associated with cyclosporin A. *BMJ* 1985;290:858.